US FDA Revokes Orphan Drug Designation For Indivior’s Sublocade

In first-of-its-kind decision, agency concludes it relied on unreasonable assumptions regarding total market size, and failed to consider information about other dosage formulations, in granting designation for buprenorphine under the cost recovery provision; however, the FDA reaffirms that scope of Sublocade’s three-year exclusivity will keep Braeburn’s Brixadi off the market for another year.

Rubber stamping that says 'Revoked'. - Image
US FDA has revoked Sublocade's orphan drug designation 25 years after it was granted. • Source: Shutterstock

Orphan drug designation for Indivior PLC’s Sublocade (buprenorphine extended-release) was improperly granted 25 years ago under the Orphan Drug Act’s cost recovery provision and should be revoked, the US Food and Drug Administration said in a first-of-its kind decision.

Based on the facts and circumstances at the time buprenorphine first received orphan drug designation for opioid addiction in 1994,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet